Heart Failure 101 The Basic Principles of Diagnosis & Management

Similar documents
Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Congestive Heart Failure: Outpatient Management

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute

State-of-the-Art Management of Chronic Systolic Heart Failure

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation

Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist

Introduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL

The ACC Heart Failure Guidelines

Updates in Congestive Heart Failure

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

Heart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none

Heart Failure: Guideline-Directed Management and Therapy

HEART FAILURE: PHARMACOTHERAPY UPDATE

Summary/Key Points Introduction

Management Strategies for Advanced Heart Failure

2016 Update to Heart Failure Clinical Practice Guidelines

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center

Outline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Heart Failure Therapies State of the Art 2017

Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018

Implementing the CardioMEMS HF System into the Management of Heart Failure Patients

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Therapeutic Targets and Interventions

Known Actions of Digoxin

Chronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH

Beyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 2/20/2017. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center

UPDATES IN MANAGEMENT OF HF

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital

Heart Failure: Current Management Strategies

What s at the Heart of the Matter?

Innovation therapy in Heart Failure

Contemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.

Heart Failure Management Policy and Procedure Phase 1

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction

Treating HF Patients with ARNI s Why, When and How?

Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017

WHAT S NEW IN HEART FAILURE

Heart Failure Medications: Who Needs What Drug Now? Disclosures

Heart Failure Medical and Surgical Treatment

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Heart Failure Update John Coyle, M.D.

Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure

The role of remote monitoring in preventing readmissions after acute heart failure

Heart Failure Update. Bibiana Cujec MD May 2015

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?

Akash Ghai MD, FACC February 27, No Disclosures

Heart Failure Clinician Guide JANUARY 2018

Update in Congestive Hear Failure DRAGOS VESBIANU MD

Updates in Heart Failure (HF) 2016: ACC / AHA and ESC

Sliwa et al. JACC 2004;44:

Heart Failure Guidelines For your Daily Practice

Module 1: Evidence-based Education for Health Care Professionals

Heart Failure Clinician Guide JANUARY 2016

Evidence of Baroreflex Activation Therapy s Mechanism of Action

FINANCIAL DISCLOSURE: No relevant financial relationship exists

2017 Summer MAOFP Update

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

CORLANOR (ivabradine) oral tablet

What s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP

9/10/ , American Heart Association 2

A patient with decompensated HF

Gina G. Mentzer, MD Cardiologist, Heart Failure & Transplant Advanced Integrated Medicine & Surgery (AIMS) Program for Heart Failure April 18 th,

Initiating New Medications in the Management of Heart Failure

Balanced information for better care. Heart failure: Managing risk and improving patient outcomes

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

HEART FAILURE KEEPING YOUR PATIENT AT HOME

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology

Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

Module 1: Evidence-based Education for Health Care Professionals

New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition

New heart failure RCT: Update on BeAT-HF in the US

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

Heart Failure, Anticoagulants, and Medication Reconciliation

PROGRESS AT LAST?: REVIEWING RECENTLY UPDATED ACCF/AHA HEART FAILURE GUIDELINES

ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration

Guideline-Directed Medical Therapy

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

Disclosure: Investigator in industry sponsored trials by Novartis

I have no disclosures. Disclosures

Heart Failure A Disease for the Internist?

Transcription:

Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence Learning Objectives Societal Impact of Heart Failure Pathophysiology Clinical Diagnosis Principles of Management Improving Heart Failure in our Community 1

What is Heart Failure? Inability of the heart to meet the oxygen demands of the body due to structural or functional abnormalities Heart failure with reduced ejection fraction (HFrEF) EF 40 % Heart failure with preserved ejection fraction (HFpEF) EF > 40 % Societal Impact of Heart Failure Affects 26 million people worldwide In 2012, 5.7 million people had a diagnosis of heart failure in the US (2.2% of population) $30.7 billion health care dollars spent Mean cost per HF related hospitalization ~ $14,632 Median length of stay: 5 days HF Readmission rate: 22.3% In 2030, it is projected that 8 million people in the US will suffer from heart failure Projected to cost $160 billion annually Readmissions, multiple drug therapy, devices, & heart transplant Associated with high morbidity and mortality In 2011, 1 in 9 death certificates cited HF as cause of death More the 50% of patients with HF die within 5 years of diagnosis Kilgore, M et al. Risk Management and Healthcare Policy. 2017:10 63 70. Farmakis D et al. Continuing Cardiology Education. 2017; 3(3), doi: 10.1002/cce2.50 How about HF Hospitalization Rates in your county? HF Hospitalization Rate per 1,000 Medicare Benificiaries, 65+, All Race, All Gender, 2012 2014 https://nccd.cdc.gov/dhdspatlas/default.aspx?state=mn 2

Pathophysiology of HFrEF: Neurohormonal Activation Beta Blockers Ivabradine ACE inhibitors ARB ARNI Nitrates Hydralazine Mineralocorticoid antagonists Diuretics Filippatos TD et al. World J Cardiol 2013; 5(9): 317 328 Clinical Diagnosis Diagnostic Tests Baseline Vitals Hypoxia, Blood pressure, Tachycardia, Tachypnea ECG Arrhythmias, MI, LBBB, AV Block Echocardiogram CXR LV Function, Structural Abnormalities Pulmonary congestion, Cardiomegaly, other causes of SOB (PTX, PNA etc) Labs BNP or NT ProBNP CBC Basic Metabolic Panel Thyroid Function LFTs Troponin Brown, P et a. Continuing Cardiology Education, 2017; 3(1), doi: 10.1002/cce2.50 Principles of Management for HFrEF Loop Diuretics Lasix Bumex Torsemide Thiazide Diuretics Metolazone Chlorthiazide Mechanical Support Diurese BB, ACEi/ARB/MA Vasodilate vs. Inotrope Diurese Cardiogenic Shock Cardiogenic Shock Vasodilators Nitroprusside Nitroglycerin Inotropes Milrinone Dobutamine Yancy, C et al. J Am Coll Cardiol 2013;62:1495 539. 3

JACC Aug 2017, 70 (6) 776 803 Appropriate Therapy Does Save Lives! On Triple Therapy (BB, ACEi/ARB/AA) Journal of the American College of Cardiology Oct 2003, 42 (7) 1234 1237 How do these new medications work? ARNI (Sacubitril Valsartan: ENTRESTO) Indications & Titration EF 35%, NYHA II III on GDMT for 3 months Can tolerate ACEi/ARB Need to stop ACEi 36 hours before starting Start 49/51 mg BID or 24/26 mg BID Max dose: 97/103 mg BID Up titrate after 2 weeks if no adverse effects (similar to ACEi or ARB) 4

How do these new medications work? (Ivabradine : CORLANOR) Indications & Titration EF 35%, NYHA II III, on GDMT for 3 months with BB at maximum dose, in sinus rhythm with HR 70 bpm at rest Start at 5 mg BID or 2.5 mg BID if history symptomatic bradycardia or conduction defects Max dose 7.5 mg BID Increase by 2.5 mg every 2 weeks to max dose or goal HR 50 60 bpm HCN: hyperpolarizaton activated cyclic nucleotide gated channel blocker Tse S, Mazzola N. Pharmacy and Therapeutics. 2015;40(12):810 814. Device Therapy for HFrEF Primary Prevention ICD All patients need to be on GDMT with beta blocker and ACEi/ARB for at least 3 months Life expectancy > 1 year ICD Criteria ICM, EF 35%, NYHA II III, 40 d post MI, or 90 d post revascularization ICM, EF 30%, NYHA I, 40 d post MI, or 90 d post revascularization NICM, EF 35%, NYHA II III CRT D Criteria EF 35%, NYHA III IV, QRS 120 ms Ideal patient w/ LBBB, QRS 150 ms Journal of the American College of Cardiology Aug 2017, 70 (6) 776 803 5

What about HFpEF? Not much data of effective medical therapies for HFpEF (EF > 40%). Treatment focused on treatment of medical comorbidities and symptoms. JACC Aug 2017, 70 (6) 776 803 Implantable Hemodynamic Monitoring: CardioMems Using Wireless Technology to measure PA pressure to combat HF Readmissions CHAMPION Trial: randomized single blind trial Device is implanted in the left PA and provides immediate assessment of PA systolic, diastolic and mean PA pressure that can monitored over time FDA approved in 2014 Indicated for HFpEF & HFrEF patients with NYHA III w/ 1 HF hospital admission in last 12 months Diuretic responsive & tolerate warfarin or Plavix/ASA for 1 month Enrolled from 64 centers in USA, N=550 (Rx: 270) Primary Endpoint: HF related admissions at six months Treatment group had 37% reduction in HF related admission compared to control group Abraham, W et al. Lancet. 2011 Feb 19;377(9766):658 66. Improving Heart Failure in Our Community Heart Failure Team of Nurse Practitioners, Pharmacists and RNs to help with HF education and have close follow up after hospitalization Tele health home monitoring systems to monitor weights to assist with early contact and intervention Working on improving online educational resources for patients Development of regional heart failure order sets to help diagnose and manage HF Any thoughts and feedback on what we can do to help you? Any suggestions? 6

Conclusions Heart Failure is a growing epidemic that has both high morbidity and mortality, as well as associated with heavy economic to our health care system Neurohormonal activation of the Renin Angiotensin Aldosterone System is the underlying mechanism for the pathophysiology of HF There are effective management strategies for HFreF, but not so much for HFpEF CardioMems is a new wireless technology that can help reduce HF readmissions We need to work together as a community to help earlier diagnose and treat HF as well as prevent HF readmissions A diagnosis is easy as long as you think about it. Soma Weiss Questions? Thoughts? Suggestions? Thank you for your attention! 7